minimal toxicity that can accurately assess disease activity and predict outcomes. In addition, while we have evidence from randomized clinical trials to support recommendations regarding initial remission induction and maintenance therapy, critical questions remain unanswered, such as the optimal duration of therapy. These gaps in knowledge reinforce the need for ongoing research in these diseases. Specific areas to investigate include the following: 1) biomarker studies to identify more